GeNeuro SA, a biopharma company developing treatments for neurological disorders and autoimmune diseases, has appointed Anke Post as chief medical officer. She succeeds David Leppert who advanced temelimab as a candidate for neurodegeneration in multiple sclerosis and launched the company’s long-Covid initiative, and who remains as a consultant. Dr Post brings 25 years in the development of drugs against psychiatric and neurodegenerative diseases, including amyotrophic lateral sclerosis.
She held leadership roles at Novartis, Eli Lilly and Co, Roche and most recently, UniQure NV, as well as in academic research. She obtained her MD from Muenster University and completed her residency and fellowship training in psychiatry, psychotherapy and neurology at the Max Planck Institute of Psychiatry in Munich, both in Germany. GeNeuro announced the appointment on January 5.